|
Genetic Analysis of Myeloproliferative Disease
|
5R01CA076167-15
|
$307,800
|
$76,950
|
COWELL, JOHN
|
AUGUSTA UNIVERSITY
|
|
Role of heat shock factors (Hsfs) in tumorigenesis
|
5R01CA132640-17
|
$270,000
|
$135,000
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy
|
1R44CA233143-01
|
$218,588
|
$109,294
|
LAMPI HERMANSON, DAVID
|
B-MOGEN BIOTECHNOLOGIES, INC.
|
|
Integrative Molecular Epidemiology of Neurocognitive Outcomes in Acute Lymphoblastic Leukemia
|
1K07CA218362-01A1
|
$166,043
|
$166,043
|
BROWN, AUSTIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mechanisms of KLF4 suppression in pediatric leukemia
|
5R01CA207086-02
|
$370,641
|
$370,641
|
LACORAZZA, DANIEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Metabolic Regulation in Leukemia-Initatiating Cells
|
5R01CA193235-04
|
$462,191
|
$115,548
|
NAKADA, DAISUKE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
$3,566
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
$7,500
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
$3,750
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
$96,094
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Using Stat3 Signaling Profiles to Understand Chemotherapy Resistance in AML
|
5R01CA175026-05
|
$379,294
|
$379,294
|
REDELL, MICHELE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia
|
5R00CA197498-05
|
$249,000
|
$124,500
|
CHEN, CHUN-WEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
The role and functional mechanism of TET1 in MLL-rearranged leukemia
|
5R01CA178454-07
|
$369,725
|
$369,725
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
The role and mechanism of FTO in leukemogenesis and drug response
|
5R01CA214965-03
|
$444,571
|
$444,571
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia
|
7R01CA182528-06
|
$392,355
|
$98,089
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting TET1 signaling to treat acute myeloid leukemia
|
7R01CA211614-02
|
$475,560
|
$237,780
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia
|
5R01CA195519-03
|
$238,425
|
$23,843
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia
|
5R01CA213131-02
|
$430,377
|
$107,594
|
KORTYLEWSKI, MARCIN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeted activation of autoimmune checkpoints in B cell malignancies
|
5R01CA157644-09
|
$410,875
|
$410,875
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics
|
5R01CA213138-02
|
$395,738
|
$395,738
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Metabolic basis of B cell lineage leukemia relapse
|
5R35CA197628-03
|
$1,035,561
|
$517,781
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
2P30CA033572-35
|
$2,543,187
|
$76,296
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S3
|
$865,000
|
$25,950
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-35S1
|
$43,750
|
$1,313
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting the ARHGAP25 pathway in acute myelogenous leukemia stem cells
|
5K08CA201591-02
|
$169,560
|
$42,390
|
WANG, LEO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Determining the role of DNMT-interacting RNAs in myeloid disorders
|
5R00CA188595-04
|
$249,000
|
$37,350
|
DI RUSCIO, ANNALISA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Mechanisms of regulation by RNA in acute myeloid leukemia
|
5R35CA197697-04
|
$1,042,185
|
$260,546
|
TENEN, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Enhancer RNA-mediated Tumor Suppressor Gene Expression in Normal and Malignant Hematopoiesis
|
5K01CA222707-02
|
$114,242
|
$28,561
|
TRINH, BON
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia
|
1R44CA224848-01A1
|
$348,768
|
$348,768
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Rapid detection of minimal residual disease in acute myeloid leukemia from peripheral blood
|
5R44CA213595-02
|
$712,071
|
$178,018
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Cohesin Mutations in Acute Myelogenous Leukemia
|
5R01CA204231-02
|
$390,712
|
$195,356
|
RAO, SRIDHAR
|
BLOODCENTER OF WISCONSIN, INC.
|
|
Discovery and targeting of apoptosis resistance mechanisms in high-risk T-ALL
|
5R01CA193651-04
|
$443,296
|
$443,296
|
GUTIERREZ, ALEJANDRO
|
BOSTON CHILDREN'S HOSPITAL
|
|
Epigenetic regulation of cellular plasticity and cancer cell fate
|
5R35CA210104-02
|
$1,062,000
|
$1,062,000
|
SHI, YANG
|
BOSTON CHILDREN'S HOSPITAL
|
|
Development of novel selective Rac inhibitors for refractory leukemias
|
5R01CA202756-03
|
$560,804
|
$560,804
|
WILLIAMS, DAVID
|
BOSTON CHILDREN'S HOSPITAL
|
|
The Role of DLST in Leukemogenesis
|
1R01CA215059-01A1
|
$377,437
|
$188,719
|
FENG, HUI
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Development of Novel Therapeutic Strategies in Human Leukemias
|
5P01CA066996-20
|
$2,247,411
|
$269,689
|
EBERT, BENJAMIN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-28
|
$5,637,954
|
$56,380
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-28S1
|
$249,965
|
$2,500
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Contribution of Gynecologic and Breast Cancer Biospecimens from African American women to HCMI
|
3P30CA043703-28S2
|
$48,000
|
$480
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
$756,064
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-05
|
$20,853,800
|
$6,986,023
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
The role of H3K79 methylation in IDH-mutant leukemia
|
5R01CA201230-04
|
$438,616
|
$438,616
|
BERNT, KATHRIN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Molecular Interactions of APOBEC3 Enzymes with the Cancer Genome
|
5K08CA212299-03
|
$148,742
|
$148,742
|
GREEN, ABBY
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers
|
1U54CA232568-01
|
$12,197,183
|
$3,537,183
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Center for pediatric tumor cell atlas
|
1U2CCA233285-01
|
$2,560,774
|
$845,055
|
TAN, KAI
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
PI3K Pathway Inhibition for Philadelphia-Like Acute Lymphoblastic Leukemia
|
5K08CA184418-05
|
$169,657
|
$169,657
|
TASIAN, SARAH
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Improving risk allocation and developing novel therapies for children with T-ALL
|
5R01CA193776-04
|
$594,741
|
$594,741
|
TEACHEY, DAVID
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Cassette exons in neoplastic pro-B-cells: implications for immunotherapy
|
1U01CA232563-01
|
$2,931,750
|
$2,931,750
|
THOMAS-TIKHONENKO, ANDREI
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Opportunities for targeted therapies generated by APOBEC3A activity in acute myeloid leukemia
|
1R21CA230065-01
|
$187,050
|
$187,050
|
WEITZMAN, MATTHEW
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Training Physician Scientists in Pediatric Oncology
|
5T32CA009659-23
|
$214,456
|
$107,228
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
Total relevant funding to Childhood Leukemia for this search: $87,288,663
|